Patent ID: 7759394

Claim:
A method of treating migraine associated with phonophobia and photophobia in a human patient within two hours of administration comprising: a) providing a liquid formulation comprising about 50 mg. of diclofenac or a pharmaceutically acceptable salt thereof in combination with an alkali metal carbonate or bicarbonate, wherein said formulation: i) is provided as a powder formulation and dissolved or suspended in water immediately before administration, or as a liquid formulation that is ingested with or without further mixing; ii) optionally has been found to achieve a maximum plasma concentration (C max ) (arithmetic mean) of from about 1500 to about 2500 ng/ml; and iii) has been found to achieve a time to maximum plasma concentration (t max ) (arithmetic mean) in from about 10 to about 25 minutes; b) orally administering said formulation to a patient suffering from migraine associated with photophobia and phonophobia, and c) thereby relieving said photophobia and said phonophobia in said patient within two hours of administration.